Speakers
Leila Abbas, Preclinical Lead, Rinri Therapeutics
Elsa Abranches, Chief Scientific Officer, ViSync Technologies
Richard Adair, Virology Senior Manager, SGS
Luca Alberici, Senior Vice President and General Manager, AGC Biologics
Cynthia Alphonse, Sustainability Manager, time matters
Nicola Ambler, Founder, The CGT Circle
Bahareh Amirloo, Lead Pharmacist for Advanced Therapy Medicinal Products, Manchester University NHS Foundation Trust
Borko Amulic, CSO/Associate Professor at University of Bristol, NeutroGen Therapeutics
Catia Andreassi, Director, AviadoBio
Claudia Andretta, Strategic Advisor, Sichem Bio
Alvaro Avivar-Valderas, Associate Director - Cell Therapy Technology & Product Engine, Takeda
Owen Bain, Director, Centre for Cell Gene Tissue Therapeutics, Royal Free NHS Trust
Chris Baldwin, Vice President, Manufacturing & Supply, Resolution Therapeutics
Robert Balfour, Investment Director, Alsa Ventures
Christopher Ballas, Chief Technology Officer, Castle Creek Biosciences
Ricardo Baptista, Chief Technology Officer, Smartcella
Tomasz Baran, Executive VP, PBKM/FamiCord Group
Samantha Barber, Chief Executive Officer, Gene People
Hollie Bartley, Group Leader, Process Development, Resolution Therapeutics
Cecile Bauche, Chief Scientific Officer, Alaya.bio
Stefano Benvenuti, Head of Public Head of Public Affairs and Market Access, Fondazione Telethon
Katja Berg, Global Director, Innovative Value and Access Strategy, Global Market Access and Pricing, BBU, AstraZeneca
Benedikt Berninger, Professor of Developmental Neurobiology, King's College London
Jessica Birt, Chief Executive Officer, Concinnity Genetics
Petter Bjorquist, CEO, VERIGRAFT AB
Jaap Jan Boelens, Chief, Stem Cell Transplantation And Cellular Therapies Pediatrics, Memorial Sloan-Kettering Cancer Center
Luca Bolondi, CEO and Co-Founder, Crane Biosciences Inc.
Angela Borghouts - de Ruijter, Senior Pricing and Market Access Manager, Cell Therapy, Gilead Sciences
Hugh JM Brady, Professor of Immunology, Imperial College London
Simon Briggs, Director, Advanced Analytics, Orchard Therapeutics
Adam Brown, Co-founder and CTO, SynGenSys & Associate Professor of Biopharmaceutical Engineering, The University of Sheffield
Henriette Burghoorn, Associate Director, Market Access, Gilead
Emmanuelle Cameau, Scientific Director Viral Vectors, Cytiva
Lara Campana, SVP, Head of Research and Translational Science, Resolution Therapeutics
Ambra Cappelletto, Principal Scientist, PureSpring Therapeutics
Paul Carter, Senior Director, MSAT, Quell Therapeutics
Anna-Lina Cavallo, Director Discovery Cell and Gene Therapy integrated Bioanalysis, AstraZeneca
Alessia Cavazza, Associate Professor in Gene Therapy, University College London
Ms Pascale Charbonnel, CBO, SCTbio
Fred Chereau, SVP, Strategy and Business Development, Alexion Pharmaceuticals
Ella Churchill, Insights Manager Life Sciences, MedCity
Giovanni Ciotta, Director - Cell Immunology, Astrazeneca
Alison Clare, Senior Research Associate, University of Bristol
Angela Columbano, Head Business Development Partnership, Genethon
Jean-Philippe Combal, Co-Founder And Chief Executive Officer, Vivet Therapeutics
Oluwayemisi Corinaldi, Senior Director, Head of EU/International Regulatory Affairs, Spark Therapeutics
Pedro Correa de Sampaio, CEO, Neobe therapeutics
Marta Costa, Principal Scientist, Stem and Immune Cells Bioengineering Lab, iBET
Matthieu Coutet, Partner, Sofinnova Partners
Vicki Coutinho, Consultant, Geni Consulting
Catriona Crombie, Head of Rare Disease Translational Challenge, LifeArc
Elisa Cuevas, Director of Client Projects, 4basebio
Salmaan Dalvi, Chief Executive Officer, Global Regenerative Medicine Society
Eric Michael David, Chief Executive Officer, BridgeBio Gene Therapy
Lindsay Davies, CSO, NextCell Pharma
Niloofar Davoodi, Cell Therapy Product Operations Lead, Takeda
Maike de la Roche, Senior Group Leader, The Cancer Research UK Cambridge Institute (CRUK-CI)
Marc de la Roche, Asst. Professor, University of Cambridge
Olga De La Rosa Morales, Madrid Cell Therapy Technology Head, Takeda
Johannes De Munter, Chief Executive Officer, Neuroplast
Carmen De Santo, Cruk New Investigator Fellow, Cancer Research UK
Isaak Decoene, Postdoctoral researcher, KU Leuven
Colleen Delaney, Founder, Chief Scientific Officer, Deverra Therapeutics, Inc.
Athanasios Didangelos, Director of Pharmacology,, Complement Therapeutics
Evi Dimitriadou, Director, Taxo Bioscience
Ben Doak, Head of Innovative Treatments, NHS England
Anne Douar, COO, Vivet Therapeutics
Marcus Droege, Senior Advisor, Market Access & Commercial, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Joseph Egan, Research Associate, Teeside University
Ms Victoria English, Co-Founder And Editor, Evernow Publications
Rui Estrela, Manager, SmartFreez, Lda
Mark Farmery, Chief Development Officer, Anocca Ab
Tim Farries, Independent Consultant Cell & Gene Therapies, Independent
Radmila Feldmann, Global manager Cell & Gene Therapies, time matters
Gregory Fiore, Former CEO, Exacis Biotherapeutics
Jonathan Fisher, Group Leader, University College London
Nerea Castillo Flores, Hematologist, Blood & Tissue Bank Center of Barcelona
Mark Flower, Vice President - Business Development, Cryopreservation, Cryoport Systems
Lydia Foeken, Chief Executive Officer, WMDA
Veronica Foisor, Field Application Scientist, Unchained Labs
David Foldes, Senior Clinical Research Fellow, Imperial College London
Katherine Forsey, Chief Research Officer, Charcot Marie Tooth Association
Miguel Forte, CEO, Kiji Tx
Daniel Fowler, Research Fellow, UCL
Nick France, Vice President, Head: Genomic Medicine Development Unit, Alexion, AstraZeneca Rare Disease
George Frodsham, Founder & CEO, MediSieve Limited
Ibon Garitaonandia, Chief Scientific Officer, cellProthera
Terri Gaskell, CTO, Rinri Therapeutics
Lina Gaydarova, Investment Manager, Novaterra
Josie Godfrey, Co-Founder and Chief Executive Officer, Realise Advocacy
Ian Goodwin, Director, Program Design and CMC Strategy, Fujifilm
Rabia Gowa, Pharmacy Lead for Innovative Treatments, NHS England
Andreja Gramc Livk, Head of Process Analytics, BIA Separations, a Sartorius Company
Roberto Gramignoli, Associate Professor, Karolinska Institutet
Klaus Graumann, CEO, Phoenestra GmbH
Uta Griesenbach, Professor, Molecular Medicine, National Heart And Lung Institute; President, British Society For Gene And Cell Therapy;, Imperial College London
Sonam Gurung, Postdoctoral Research Fellow, University College London
NAGY HABIB, Professor of Surgery, Imperial College London
Ben Hajir, Senior Business Development Manager, Abselion
Eric Halioua, President & Chief Executive Officer, PDC*line pharma SA
William Hall, Senior Process Technical expert, Autolus
Tom Hargroves, Consultant, Belmont Bio Consulting
Matthias Hebben, CTO, Complement Therapeutics
Stijn Heessen, Chief Operating Officer, Alder Therapeutics
Laura Herbst, Group Manager, Fraunhofer-Institute for Production Technology
Victor Hernandez, CSO, Axovia Therapeutics
Diana Hernandez, Director of Immune and Advanced Therapies, Anthony Nolan
David Hipkiss, Executive Chair, AlveoGene
Tom Hoggan, Founder, Hoggan Biotech Consulting
Lilian Hook, Director of Cell, Aphaeresis and Gene Therapies, NHS Blood and Transplant
Volker Huppert, Chief Operating Officer, Glycostem Therapeutics BV
Mr Adam Inche, CEO, Lentitek
Claire Irvine, Of Counsel, Beck Greener LLP
Reagan Jarvis, Chief Executive Officer, Anocca Ab
James Jones, Honorary Consultant in Medical Oncology, University of Cambridge
Ron Jortner, Founder & Chief Executive Officer, Aspire Biosciences
Margareth Jorvid, Head of Regulatory Affairs, Ilya Pharma
Angela Justice, Chief People Officer / Executive Advisor, Justice Group Advisors
Rahul Khetan, Venture Associate, UCB Ventures
Sven Kili, Partner, Saisei Ventures
Lorenz Knackstedt, Chief Technology Officer & Co-Founder, NeutroGen Therapeutics
Laura Koivusalo, Chief Executive Officer & Founder, StemSight
Anna Koptina, Head Of Regulatory Affairs, Mendus
Bence Kozma, Research Assistant PostDoc, TU Wien
Mathias Kroll, Chief Business Officer, Cynata Therapeutics Ltd
David Kuntin, Chief Executive Officer, Mesenbio
Joanne Kurtzberg, Director, Marcus Center For Cellular Cures,, Duke University Medical Center
Lukasz Kwiatkowski, Product Development Supervisor, TC Biopharm
Michael Kyriakides, Investment partner, Syncona Ltd
Holger Laux, Director of Viral Vector Process Development, CSL Behring
Inês Leal Reis, Co-founder, Regenera
Juliette Lee, VP, EQT Life Sciences
Michelle Levene, Managing Director, 161 Consulting Ltd
James Levine, President, Fondation Ipsen
Daniel Lewi, Co-founder & Chief Executive Officer, The Cure & Action for Tay-Sachs (CATS) Foundation
John Lewis, Project Manager, Advanced Therapies Wales and Midlands-Wales Advanced Therapy Treatment Centre
Robert Leydon, Group Leader, AAV, Oxgene A Wuxi Advanced Therapies Company
Charles Li, Chief Business Officer, AAVnerGene
Laura Lombardi, Director of Pharmacology and Gene Therapy Research, Tenaya Therapeutics
Eleuterio Lombardo, Director of Cell Therapy Characterization & Development, Cell Therapies, Takeda
Jacek Lubelski, CTO, R&D Operations and Product Development, NanoCell Therapeutics
Dominika Lukas, Associate Director of Allogeneic Immunotherapy, R&D, Miltenyi Biotec
Shirley M Bartido, Director, Global Regulatory Affairs Oncology Cell Therapy, Takeda
John Maher, CSO, Leucid Bio
Salmah Mahmood Ahmed, Director of Quality and Regulation, Anthony Nolan
Heather Main, Project Manager,, ATMP Sweden
Qasim Majid, Postdoctoral Research Scientist, University of Helsinki
Alberto Malerba, Lecturer in Gene Therapy, Royal Holloway University of London
Karl Johan Malmberg, Director, Precision Immunotherapy Alliance, Professor, The University of Oslo
Anders Månsson, Chief Executive Officer, PHI
James March, Postdoctoral Research Assistant, Royal Holloway, University of London
Julius Mathews, Project Manager & Research Fellow, Fraunhofer Institute for Production Technology IPT
Marc-Olivier Mignon, Chief Executive Officer, CELLforCURE by SEQENS
Anji Miller, Skills Lead, Innovation Hubs for Gene Therapies/Director Translational Skills, LifeArc
Manal Mohammed, Senior Lecturer, University of Westminster
Deana Mohr, Chief Executive Officer, MUVON Therapeutics
Dame Molly Morag Stevens, John Black Professor of Bionanoscience, University of Oxford
Paolo Morgese, Vice President, Public Affairs, Europe, Alliance for Regenerative Medicine
David Morrow, Senior scientific manager, EATRIS
Sophie Mountcastle, Network Manager - Innovation Hubs for Gene Therapies, Innovation Hubs for Gene Therapies
Noor Mujahid, Head of Vector Process Development, NHS Centre for Cell Gene and Tissue Therapeutics
Matthias Müllner, CEO, bespark*bio
Claudio Mussolino, Group Leader - Genome and Epigenome Engineering, Freiburg University Medical Center
Alexander Natz, Secretary General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Darren Nesbeth, Programme Director, University College London
Katy Newton, Former Senior Vice President of Immunology and Process Development, Achilles Therapeutics Limited
Roberto Nitsch, Director, AstraZeneca
Theres Oakes, Former Head of Translational Science Product Characterisation, Achilles Therapeutics Limited
Kieran O'Donnell, Director, Kieran O'Donnell Ltd
Raphael Ognar, President & Chief Executive Officer, Co-Founder, NKILT Therapeutics Inc.
Matias Olsen, Senior Manager, Public Affairs & Policy, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Brian O'Mahony, Chief Executive Officer, Irish Haemophilia Society
Nneka Onwudiwe, Former PRO/PE Regulatory Review Officer, Food and Drug Administration (FDA)
Dominic O'Regan, Business Development Consultant & Investor, New Mosaic
Maitane Ortiz Virumbrales, Associate Director, Cell Therapies, Takeda
George Pamenter, PhD Researcher, UCL
Francis Pang, Senior Vice President, Global Market Access and Geographic Expansion, Orchard Therapeutics
Sarita Panula, Head of R&D and CMC, StemSight
Anna-Pia Papageorgiou, Policy Officer, European Commission
Kerstin Papenfuss, Director Pharma, Deep Science Ventures
Mrs Trish Parry, Founder and Managing Director, INDICRO Ltd
Tanya Patel, Manager CTSM GCP Operations, BioNTech
Shree Patel, Biotech and Life Sciences Consultant, Suriacon Consulting
Kinnari Patel, President, Head of R&D and COO, Rocket Pharma
Dilip Patel, SVP, Pricing, Value & Access Strategy, Autolus
Ashish Patel, Clinical Senior Lecturer in Vascular Surgery, King’s College London & Guy’s and St Thomas’ Hospital NHS Foundation Trust
Tom Payne, Chief Operating Officer, Laverock Therapeutics
Valentina Pennucci, Principal Scientist, Global Analytics, Orchard Therapeutics
David Peritt, Chief Scientific Officer, Lupagen
Brian Philip, Primary Scientist, NIBRT
Rupa Pike, Global Head of Strategic Alliances, Catalent
Riccardo Privolizzi, Senior Research Fellow, University College London
Nivetha R, CMC Specialist, Leucid Bio
Shahrooz Rabizadeh, CEO & Co-Founder, Sagittarius Bio, Inc
Linda Randall, Associate Vice President, Biologics Development, Manufacturing & Control, Pharmaron
Lior Raviv, CTO, Pluri
Nicola Redfern, Director, NJ Redfern Ltd.
Pilar Redondo, Site Head Madrid, Cell Therapy Technology Center, Takeda
Ajan Reginald, CEO, Roquefort Therapeutics PLC
Jack Reid, Co-founder, Unicorn Bio
Giovanni Rizzo, Partner Biotech Fund, Indaco Venture Partners
Michael Roberts, CEO, Chromatin Bioscience
Jessica Robinson, PD, Terrapinn
Miguel Rodrigues, Co-Founder, Smartfreez
Antonio Roldao, Head of Cell-based Vaccines Development Lab, IBET
Alex Ross, Chair of Cord Blood Operations Committee, WMDA
Jeroen Rovers, Chief Medical Officer, Mendus
Sean Russell, Head of Regulatory Affairs, Telethon Foundation
Tara Sadeghi, Chief Operating Officer, Cellenkos
Arthur Sagoskin, Chief Executive Officer & Co-Founder, Mygogenesis
Chaminda Salgado, CMC Innovation Lead, CEPI
Mark Sawicki, President & CEO, Cryoport Systems
Jordan Schecter, Vice President | Multiple Myeloma DAS Leader, Johnson and Johnson
Christian Schutt, Senior Scientist, CSL Behring Innovation GmbH
Fatma Senkesen, Executive Director, Head Divisional Projects, Lonza
Marta Serafini, Associate Professor, School of Medicine and Surgery, University of Milano-Bicocca
Will Sherlock, Senior Scientist, Rinri Therapeutics
Anthony Shillings, Head of Vector Production, NHS Centre for Cell Gene and Tissue Therapeutics
Simon Sioen, Field Application Scientist, TrinceBio
Chrysanthi Sitmalidou, Scientist II, Orchard Therapeutics
Julia Skokowa, Head, Translational Oncology, Dept. Hematology and Oncology. Director Gene and RNA Therapy Center, University Hospital Tübingen
Owen Smith, Partner, 4BIO Capital
Jorge Soza Ried, Head of Therapeutic Virus Development Laboratory, Boehringer Ingelheim Pharma GmbH&Co.KG
Oliver Spadiut, Univ. Professor & Head of the Research Area Biochemical Engineering, TU Wien
Mike Spencer, Vice President of Oncology Market Access, Johnson & Johnson
Mark Stockdale, Senior Director, Strategic Alliances, Asimov
Matthias Stöcker, Regulatory Capability Lead, Boehringer Ingelheim International GmbH
Weiheng Su, Head of AAV, Oxgene A Wuxi Advanced Therapies Company
Stephen Sullivan, COO, iPSirius
Mathias Svahn, Chief Executive Officer, NextCell Pharma
Nathan Sweeney, ATMP Technical Strategy Director, Rentschler Biopharma
Hiroki Takai, Director, Investment Group, UK Office, Global Brain
Marina Tarunina, Research Director, Plasticell
Benjamin Taylor, Senior Director, Cell Immunology, AstraZeneca
Anike Te, Chief Strategy Officer, Lucideon
Dr. Panteli Theocharous, Chief Therapeutics Officer, Garuda Therapeutics, Inc.
Stefanos Theoharis, Chief Executive Officer, OneChain Immunotherapeutics
Kayleigh Thirlwell, Director - Translational In Vitro Pharmacology, Resolution Therapeutics
Steven Thompson, Vice President, Sales - Cell Processing, BioLife Solutions
Pamela Tranter, Head, Translational Research Group, Translational Research Office, University College London
Marco Traub, Chief Executive Officer, Tesct—Society
Tim Traynor, Technical Sales Specialist, Aldevron
Kristian Tryggvason, Chief Executive Officer, Alder Therapeutics
Sheela Upadhyaya, Life Science Advisor in Rare Diseases & Special Advisor, Openflex Ltd
Hiro Usuda, Scouting & Transaction Lead, Business Development, Astellas Pharma Europe Ltd
Renaud Vaillant, CEO, Alaya.bio
Sonia Valero, Head Of Clinical Operations - Patient Advocacy Leader, Vivet Therapeutics
Giuliana Vallanti, Vice President of Development and R&D for Cell & Gene Therapy, AGC Biologics
Jan Van Hauwermeiren, VP Business Development, Trince
David Venables, Chief Executive Officer, Laverock Therapeutics
Joshi Venugopal, General Manager and Head of Europe, Novartis Gene Therapies
Valentin von Werz, PhD Student, TU Wien
Alain Wagner, Director of Research, CNRS
Qizhao Wang, CTO, AAVnerGene
Ruizhi Wang, Chief Executive Officer/Founder, Abselion
Emily Warner, Principal Scientist, Ikarovec Limited
Ben Weil, Director of Manufacturing, INmune Bio
Adrian Westhaus, Postdoctoral Researcher, Genethon
Caroline Weydert, Regional Specialist Genomics (Biopharma), Bio-Rad
Darius Widera, Professor of Stem Cell Biology and Regenerative Medicine, University of Reading
Chris Williams, Chief Business Officer, Autolus Therapeutics
Kate Witkowska, Strategic Partnerships Director, Genomics England
Tim Witney, Professor of Molecular Imaging, Kings College London
Craig Woods, 07561524791, Forge Genetics
Su Xiao, Chief Technical Operations Officer, Neurophth Therapeutics
Shao-An Xue, Professor, Zhengzhou University of Technology
Ilya Yasny, Partner, LanceBio Ventures
Mana Yen, Global Executive Director - Health systems, Novartis Gene Therapies
Andrea Zobel, Senior Director, Personalized Supply Chain, World Courier
Get Involved with Advanced Therapies Congress
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events